SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
复制标题
DOI：
10.1016/j.cell.2021.12.046
复制
发表时间：
2022-02-03
期刊：
影响因子：
64.5
通讯作者：
Screaton GR
中科院分区：
文献类型：
--
作者：
Dejnirattisai W;Huo J;Zhou D;Zahradník J;Supasa P;Liu C;Duyvesteyn HME;Ginn HM;Mentzer AJ;Tuekprakhon A;Nutalai R;Wang B;Dijokaite A;Khan S;Avinoam O;Bahar M;Skelly D;Adele S;Johnson SA;Amini A;Ritter TG;Mason C;Dold C;Pan D;Assadi S;Bellass A;Omo-Dare N;Koeckerling D;Flaxman A;Jenkin D;Aley PK;Voysey M;Costa Clemens SA;Naveca FG;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Baillie V;Serafin N;Kwatra G;Da Silva K;Madhi SA;Nunes MC;Malik T;Openshaw PJM;Baillie JK;Semple MG;Townsend AR;Huang KA;Tan TK;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Constantinides B;Webster H;Crook D;Pollard AJ;Lambe T;OPTIC Consortium;ISARIC4C Consortium;Paterson NG;Williams MA;Hall DR;Fry EE;Mongkolsapaya J;Ren J;Schreiber G;Stuart DI;Screaton GR
2021 年 11 月 24 日，公布了新的 SARS-CoV-2 病毒分离株 Omicron-B.1.1.529 的序列，其 Spike (S) 突变数量远多于之前报道的变种。感染早期大流行 Alpha、Beta、Gamma 或 Delta 的疫苗接种者和恢复期受试者的血清中 Omicron 的中和滴度大幅降低，或者血清未能中和。第三剂疫苗可提高针对 Omicron 的滴度，并且在接种疫苗的个体和感染 Delta 的个体中，其滴度都很高。 Omicron 中的突变会敲除或大幅减少大部分强效单克隆抗体和商业开发中的抗体的中和作用。 Omicron S 与早期病毒相比发生了结构变化，并利用突变与 ACE2 紧密结合，以释放由免疫逃逸驱动的进化。这导致 ACE2 结合位点发生大量突变，并重新平衡受体与早期大流行病毒的亲和力。 Omicron 中和滴度大幅降低，通过第三次加强疫苗改善 许多有效的 mAb 未能中和 Omicron 复杂的突变模式平衡了 ACE2 结合和抗体逃逸 Omicron RBD 结构相似，但抗原性最远的变体 对疫苗接种者、先前感染多种变体的康复患者和强效单克隆抗体的血清进行全面分析 COVID-19 大流行早期的抗体显示，中和 SARS-CoV-2 Omicron 变体的能力整体大幅下降，而第三剂疫苗似乎可以改善这种情况。 Omicron RBD 的结构分析表明，选择性压力平衡了增加 ACE2 亲和力的关键变化与不利于 ACE2 结合但促进免疫逃逸的受体结合基序的其他变化。
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses. Large reduction in Omicron neutralization titers, ameliorated by the 3rd booster vaccine Failure of many potent mAbs to neutralize Omicron Complex pattern of mutations balances ACE2 binding and antibody escape Omicron RBD is structurally similar but the most antigenically distant variant A comprehensive analysis of sera from vaccinees, convalescent patients previously infected by multiple variants, and potent monoclonal antibodies from early in the COVID-19 pandemic reveals a substantial overall reduction in the ability to neutralize the SARS-CoV-2 Omicron variant, which seems to ameliorate with a third vaccine dose. Structural analyses of the Omicron RBD suggest that selective pressure balances key changes that increase affinity for ACE2 with other changes in the receptor-binding motif that disfavor ACE2 binding but facilitate immune escape.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.8
作者：
Jumper J;Evans R;Pritzel A;Green T;Figurnov M;Ronneberger O;Tunyasuvunakool K;Bates R;Žídek A;Potapenko A;Bridgland A;Meyer C;Kohl SAA;Ballard AJ;Cowie A;Romera-Paredes B;Nikolov S;Jain R;Adler J;Back T;Petersen S;Reiman D;Clancy E;Zielinski M;Steinegger M;Pacholska M;Berghammer T;Bodenstein S;Silver D;Vinyals O;Senior AW;Kavukcuoglu K;Kohli P;Hassabis D
通讯作者：
Hassabis D
DOI：
10.3390/ijerph18084172
发表时间：
2021-04-15
影响因子：
--
作者：
Colmenares-Mejía CC;Serrano-Díaz N;Quintero-Lesmes DC;Meneses L;Salazar Acosta I;Idrovo ÁJ;Sanabria-Echeverry DY;Cordero-Rebolledo H;Castillo V
通讯作者：
Castillo V
影响因子：
64.5
作者：
Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
64.8
作者：
Ke, Zunlong;Oton, Joaquin;Briggs, John A. G.
通讯作者：
Briggs, John A. G.